Abstract: An anti-PD-1 antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-PD-1 antibody or the antigen-binding fragment thereof has high specificity and high affinity to PD-1, and can effectively block the binding of PD-1/PD-L1 and PD-1/PD-L2 so as to activate the immune system, thereby achieving the effect of inhibiting tumor growth. Therefore, a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof and a use of the pharmaceutical composition in preparation of drugs are further comprised. The drugs are used for preventing and/or treating tumors, infections, or autoimmune diseases.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: Provided are an anti-Nectin-4 antibody or antigen-binding fragment thereof, an antibody conjugate comprising the same, and use thereof in the manufacture of a medicament, particularly in the manufacture of a medicament for treating and/or preventing cancer.

Abstract: Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: Related is an anti-CLDN 18.2 antibody-drug conjugate, preparation method and use thereof. The antibody-drug conjugate and the composition thereof is capable of effectively binding CLDN 18.2 and inhibiting the growth of Claudin 18.2 positive tumors. Further related is a pharmaceutical composition comprising the antibody-drug conjugate or the composition, and use of the pharmaceutical composition in the preparation of a medicament for preventing and/or treating tumors.

Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.

Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.

Abstract: Related are an anti-TSLP antibody or an antigen-binding fragment thereof, nucleic acid molecules coding the same, and a method for preparing the same. The anti-TSLP antibody or the antigen-binding fragment thereof have high affinity to TSLP, capable of effectively binding with TSLP and blocking the proliferative effect of TSLP with respect to Ba/F3-hTSLPR-hIL7R? cells, and blocking the capability of TSLP in activating and secreting cytokines with respect to PBMC. At the same time, further related are a medicinal composition comprising the antibody or the antigen-binding fragment thereof, and uses of the composition in preparing a medicament for preventing and/or treating asthma, allergic inflammation, an allergic reaction or autoimmune disease.

Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.

Abstract: The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.

Abstract: Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3? molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.

Abstract: Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.

Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.

Abstract: Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3? molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.